ValuEngine upgraded shares of Genomic Health (NASDAQ:GHDX) from a sell rating to a hold rating in a research note issued to investors on Friday morning.
Several other equities analysts also recently issued reports on the stock. Cowen restated a hold rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, September 1st. Canaccord Genuity restated a buy rating and issued a $39.00 price objective on shares of Genomic Health in a research note on Wednesday, November 15th. Jefferies Group restated a hold rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, October 20th. Zacks Investment Research upgraded shares of Genomic Health from a sell rating to a hold rating in a research note on Friday, October 13th. Finally, J P Morgan Chase & Co downgraded shares of Genomic Health from a neutral rating to an underweight rating and set a $25.00 price objective for the company. in a research note on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $31.57.
Genomic Health (NASDAQ GHDX) opened at $35.55 on Friday. Genomic Health has a 12 month low of $26.37 and a 12 month high of $35.57.
A number of institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio purchased a new position in Genomic Health in the third quarter valued at about $444,000. GSA Capital Partners LLP increased its holdings in Genomic Health by 43.7% in the third quarter. GSA Capital Partners LLP now owns 63,100 shares of the medical research company’s stock valued at $2,025,000 after buying an additional 19,200 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Genomic Health in the third quarter valued at about $138,000. Point72 Asset Management L.P. purchased a new position in Genomic Health in the third quarter valued at about $350,000. Finally, Jane Street Group LLC purchased a new position in Genomic Health in the third quarter valued at about $227,000. 89.76% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Genomic Health (GHDX) Upgraded at ValuEngine” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2017/12/18/genomic-health-ghdx-upgraded-at-valuengine.html.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.